Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial-Reference-Cited by-同舟云学术

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Published:2018-03 Issue:3 Volume:175 Page:225-231
ISSN:0002-953X
Container-title:American Journal of Psychiatry
language:en
Short-container-title:AJP

Author:

McGuire Philip¹,Robson Philip¹,Cubala Wieslaw Jerzy¹,Vasile Daniel¹,Morrison Paul Dugald¹,Barron Rachel¹,Taylor Adam¹,Wright Stephen¹

Affiliation:

1. From the Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Medical University of Gdansk, Gdansk, Poland; the Department of Psychiatry, “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest, Romania; GW Pharmaceuticals and the Cannabinoid Research Institute, Research and Development, GW Pharmaceuticals, Cambridge, U.K.

Publisher

American Psychiatric Association Publishing

Subject

Psychiatry and Mental health

Cited by 463 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anandamide in disease: Role in psychosis;Anandamide in Health and Disease;2025

2. In the weeds: A comprehensive review of cannabis; its chemical complexity, biosynthesis, and healing abilities;Toxicology Reports;2024-12

3. Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials;Frontiers in Pharmacology;2024-09-11

4. Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review;European Journal of Pharmacology;2024-09

5. Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol;Psychiatry Research;2024-09